Vesalius Biocapital Partners

Headquartered in Luxembourg, Vesalius Biocapital Partners is a European life sciences venture firm investing in human health companies built around proprietary technologies. Its sub-vertical focus spans biotech and medical devices, and while the firm operates from Europe, its mandate explicitly extends to global markets. AI is not a stated focus area; the thesis is rooted in scientific differentiation and clinical translation rather than software-driven categories.

Vesalius participates at Series A and Series B, writing checks in the $5M to $25M range. That positioning makes it a meaningful lead or co-lead candidate for European biotech and medtech companies past the initial seed stage that need capital to advance clinical milestones or product launches. Cross-border deals are within scope given the firm’s stated global posture, although European startups will generally find the geographic fit most natural.

Founders pitching Vesalius should arrive with strong proprietary technology, clear scientific rationale, and a credible regulatory and clinical path. Series A readiness implies a defined lead asset or product, validated preclinical or early clinical data, and a team with operational depth in life sciences. Limited public information is available on portfolio cadence, so warm introductions through European life sciences networks are advisable.